%0 Journal Article %A Andrea M. D'Armini %A Hossein-Ardeschir Ghofrani %A Nick H. Kim %A Eckhard Mayer %A Gerald Simonneau %A Martin R. Wilkins %A Tomás Pulido %A Arno Fritsch %A Neil Davie %A Marius M. Hoeper %T Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study %D 2013 %J European Respiratory Journal %P P2598 %V 42 %N Suppl 57 %X BackgroundPEA is the treatment of choice for CTEPH, but a proportion of patients (pts) are ineligible or have persistent/recurrent PH after PEA. CHEST-1 showed that riociguat is a promising therapy for such pts, as it improved 6-min walking distance (6MWD), hemodynamics, WHO functional class (FC), and NT-proBNP.AimsTo determine the proportion of pts in CHEST-1 who achieved responder thresholds shown previously to correlate with improved outcome in pts with other forms of PH, at baseline (BL) and after targeted therapy.MethodsIn this randomized, double-blind, Phase III study, pts received placebo (pbo) or individually titrated riociguat (up to 2.5 mg tid) for 16 wks. The criteria of a positive response were: 6MWD increase ≥30 m and ≥40 m, 6MWD ≥380 m, cardiac index (CI) ≥2.5 L/min/m2, PVR <500 dyn·s·cm-5, SvO2 ≥65%, FC I/II, and NT-proBNP <1800 pg/mL.ResultsThe proportion of pts meeting these criteria at BL and Wk 16 is shown below. At BL, the proportions were similar in the pbo and riociguat arms. Riociguat increased the proportion of pts achieving these criteria at Wk 16; minimal improvements or decreases were seen in the pbo arm for most parameters.View this table:ConclusionsRiociguat increased the proportion of CTEPH pts achieving criteria defining a positive response to therapy. %U https://erj.ersjournals.com/content/erj/42/Suppl_57/P2598.full.pdf